Alcon offers to take over biotech firm ESBATech

09/14/2009 | Reuters

Alcon is in a definitive agreement to acquire ESBATech, a clinical-stage biotech firm in Switzerland, for $150 million in cash and as much as $439 million in milestone dues. The deal would give Alcon access to ESBATech's eye treatment technology and expand its research capability.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC